Reply to: "Contradictory advice for people who inject drugs in the 2016 EASL Recommendations on Treatment of Hepatitis C".
出版信息
J Hepatol. 2017 May;66(5):1103. doi: 10.1016/j.jhep.2017.01.021. Epub 2017 Feb 3.
PMID:28167321
Abstract
摘要
相似文献
1
Reply to: "Contradictory advice for people who inject drugs in the 2016 EASL Recommendations on Treatment of Hepatitis C".
J Hepatol. 2017 May;66(5):1103. doi: 10.1016/j.jhep.2017.01.021. Epub 2017 Feb 3.
2
Contradictory advice for people who inject drugs in the 2016 EASL Recommendations on Treatment of Hepatitis C.
J Hepatol. 2017 May;66(5):1101-1103. doi: 10.1016/j.jhep.2016.12.028. Epub 2017 Feb 3.
3
Hepatitis C virus treatment as prevention in people who inject drugs.
Lancet Infect Dis. 2018 Apr;18(4):379. doi: 10.1016/S1473-3099(18)30130-0. Epub 2018 Mar 21.
4
Time to end treatment restrictions for people with hepatitis C who inject drugs.
Lancet Gastroenterol Hepatol. 2018 Mar;3(3):142-143. doi: 10.1016/S2468-1253(18)30001-3. Epub 2018 Jan 6.
5
Prioritising treatment among people who inject drugs in order to eliminate hepatitis C: addressing reluctance with sound economic analyses.
Gut. 2017 Dec;66(12):2052-2053. doi: 10.1136/gutjnl-2016-312636. Epub 2016 Aug 26.
6
How to eliminate HCV in people who inject drugs in the USA.
Lancet Infect Dis. 2018 Feb;18(2):134-135. doi: 10.1016/S1473-3099(17)30678-3. Epub 2017 Nov 15.
7
The changing landscape of hepatitis C treatment-not 'can we cure?' but 'who should we cure first?' Is this an ethical approach?
Addiction. 2015 Jun;110(6):984-5. doi: 10.1111/add.12912.
8
Hepatitis C virus infection in people who inject drugs in Africa.
Lancet Infect Dis. 2020 Mar;20(3):283-284. doi: 10.1016/S1473-3099(20)30051-7.
9
Hepatitis C virus infection in people who inject drugs in Africa.
Lancet Infect Dis. 2020 Mar;20(3):282-283. doi: 10.1016/S1473-3099(20)30049-9.
10
Strategies for achieving universal access to hepatitis C virus prevention and care for people who inject drugs.
Int J Drug Policy. 2015 Nov;26(11):1039-40. doi: 10.1016/j.drugpo.2015.07.008. Epub 2015 Jul 17.
引用本文的文献
1
Hep-CORE: a cross-sectional study of the viral hepatitis policy environment reported by patient groups in 25 European countries in 2016 and 2017.
J Int AIDS Soc. 2018 Apr;21 Suppl 2(Suppl Suppl 2):e25052. doi: 10.1002/jia2.25052.
2
Policy responses to hepatitis C in the Nordic countries: Gaps and discrepant reporting in the Hep-Nordic study.
PLoS One. 2018 Jan 30;13(1):e0190146. doi: 10.1371/journal.pone.0190146. eCollection 2018.
Zotero 插件